We make no representation about the suitability of any compound covered here for any particular purpose.
On October 8, 2024, an FDA advisory panel voted on six bulk drug substances for compounding. The decision directly affects tirzepatide and semaglutide. It also touches peptides like BPC-157, MK-677, Semax, and Hexarelin. The VA's new alcohol trial adds urgency. Researchers need compounded tirzepatide. The panel's vote may restrict supply.
The FDA Panel's Six-Peptide Vote
The Pharmacy Compounding Advisory Committee met to review six substances. The list: BPC-157, MK-677, Semax, Hexarelin, and two others. The panel voted on whether each should be allowed for compounding. The outcome was mixed. Some peptides got a "no." Others got a "yes." The details matter for tirzepatide access.
BPC-157, a peptide studied for tissue repair, was rejected. MK-677, a growth hormone secretagogue, also failed. Semax, a nootropic, and Hexarelin, a GH secretagogue, faced similar fates. The FDA panel's six-peptide vote signals tighter oversight. This affects compounding pharmacies nationwide.
Tirzepatide and Semaglutide in the Crosshairs
Tirzepatide and semaglutide are not on the six-peptide list. But the vote sets a precedent. The FDA is scrutinizing all compounded peptides. A 2023 review found quality issues in compounded GLP-1s. The agency found subpotent tirzepatide in some samples. This led to warnings. The FDA's findings on subpotent tirzepatide raised alarms.
Compounded semaglutide faces similar pressure. Online sales have boomed. But the FDA warns about safety. A 2024 investigation uncovered inconsistent dosing. The FDA warnings reshape compounded semaglutide online. The panel's decision may accelerate restrictions.
The VA's New Alcohol Trial
The Department of Veterans Affairs launched a trial in 2024. It tests tirzepatide for alcohol use disorder. The study needs compounded tirzepatide. Why? The trial uses specific doses not available commercially. Compounding pharmacies fill that gap. If the FDA restricts compounding, the trial could stall.
The VA's trial is a randomized, double-blind study. It enrolls 200 veterans. The primary endpoint is reduction in heavy drinking days. Tirzepatide's GLP-1/GIP action may curb cravings. A 2022 pilot study showed promise. Now the panel's vote threatens supply.
How the Six-Peptide Decision Impacts Tirzepatide Access
The panel's vote does not ban tirzepatide compounding directly. But it creates a chilling effect. Compounding pharmacies may stop producing GLP-1s. Fear of FDA enforcement is real. The agency has already sent warning letters. The FDA investigates compounded tirzepatide aggressively.
Three factors are at play: 1) The FDA's heightened scrutiny. 2) State pharmacy boards following federal lead. 3) Liability concerns for compounders. The result: fewer pharmacies willing to make tirzepatide. Prices could rise. The VA trial may face delays.
Who's Affected
Veterans in the alcohol trial are the most immediate group. They rely on consistent tirzepatide supply. Researchers need GMP-grade material. Compounding pharmacies provide that. If access tightens, the trial's timeline extends. Costs could jump from $48 per vial to $200 or more.
Patients using compounded semaglutide for weight loss are also affected. Many pay out of pocket. A month's supply runs around $200. If compounding dries up, they face branded options at $1,000+. The panel's vote on peptides like BPC-157 and MK-677 shows the FDA's direction. All compounded peptides are under review.
What to Watch Next
The FDA will issue a final rule on the six peptides. That could come in early 2025. The agency may add tirzepatide and semaglutide to a "do not compound" list. Watch for updates to the FDA's 503A Bulks List. The VA trial's progress is another signal. If recruitment slows, compounding access is likely the cause.
State pharmacy boards may act before the FDA. Some states already restrict GLP-1 compounding. The National Association of Boards of Pharmacy tracks this. Check their website for alerts. The compounding industry will likely sue if restrictions are too broad. A 2023 lawsuit challenged similar FDA actions.
All data presented is sourced from publicly available scientific literature. No personal experience or testimonial is implied.